跳至主要内容
临床试验/NL-OMON49647
NL-OMON49647招募中2 期

A pilot study on oral esketamine for depression and demoralization in patients with advanced cancer receiving palliative care - Esketamine for depression and demoralization

niversitair Medisch Centrum Groningen0 个研究点目标入组 10 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • In order to be eligible to participate in this study, a subject must meet all
  • of the following criteria:
  • Older than 18 years of age;
  • Sufficient understanding of spoken and written Dutch;
  • DSM-5 diagnosis of MDD, first or recurrent episode, ascertained by the Mini
  • International Neuropsychiatry Interview (MINI-plus) and/or demoralization as
  • indicated by a score of 30 on the Demoralization Scale;
  • Advanced malignancy with no curative antitumor treatment possibilities as
  • determined by a physician at the oncology department.

排除标准

  • - Depression with psychotic features, according to the DSM-5;
  • - Previous or comorbid schizophrenia spectrum or other psychotic disorder
  • according to the DSM-5, not including previous MDD with psychotic features;
  • - Comorbid moderate or severe dependence of alcohol or drugs according to the
  • DSM-5, not including tobacco-related and caffeine-related disorders;
  • - Comorbid delirium, according to the DSM-5;
  • - Recent (within the last 4 weeks) or current use of non-prescribed
  • psychoactive compounds, including cannabis and Saint John*s wort;
  • - Electroconvulsive therapy (ECT) sessions or antidepressant treatment changes
  • planned for the period of the study;
  • - Current use of benzodiazepines and benzodiazepine-like agents (zolpidem,
  • zopiclone) in excess of 2 mg lorazepam or an equivalent per day;
  • - Current use of ketamine;
  • - Mental incompetence to provide informed consent;
  • - Presence of any contra-indication for ketamine use. Ketamine is
  • contra-indicated in persons with uncontrolled blood pressure, persons whom have
  • shown hypersensitivity to the drug or its components, in persons with eclampsia
  • or pre-eclampsia, severe coronary or myocardial disease, or a cerebrovasculair
  • accident or cerebral trauma, and in patients who use medication that ketamine
  • interacts with on a major level, such as monoamine oxidase inhibitors (MAOi).
  • - Inability to comply with treatments and/or assessments.

研究者

相似试验

A pilot study on oral esketamine for depression and... | 临床试验